<p>隨着全球市場應對美國與中國之間重新出現的貿易緊張局勢和經濟不確定性，投資者越來越關注亞洲的小型股以尋找潛在機會。在這種環境下，識別出在地緣政治挑戰中展現出韌性和增長潛力的公司，可能是發現有前景投資的關鍵。</p>
<h3>亞洲基本面強勁的十大未被發現的寶藏</h3>
<table>
<thead>
<tr>
<th>名稱</th>
<th>負債權益比</th>
<th>收入增長</th>
<th>盈利增長</th>
<th>健康評級</th>
</tr>
</thead>
<tbody>
<tr>
<td>Woori Technology Investment</td>
<td>NA</td>
<td>11.06%</td>
<td>-3.63%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>廣州德信熱能科技</td>
<td>6.90%</td>
<td>-5.77%</td>
<td>22.35%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>無錫化工設備</td>
<td>NA</td>
<td>12.94%</td>
<td>1.09%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>東北鋼鐵</td>
<td>NA</td>
<td>5.45%</td>
<td>0.39%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>紅綿智慧科技創新有限公司（廣州）</td>
<td>12.09%</td>
<td>-20.53%</td>
<td>52.26%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Wholetech System Hitech</td>
<td>6.48%</td>
<td>14.41%</td>
<td>19.21%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>深圳凱安電子科技</td>
<td>3.22%</td>
<td>-6.05%</td>
<td>-14.83%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>CTCI 先進系統</td>
<td>33.93%</td>
<td>20.38%</td>
<td>21.25%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>金利華電氣</td>
<td>53.05%</td>
<td>9.84%</td>
<td>44.18%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Mirai Semiconductors</td>
<td>46.15%</td>
<td>10.52%</td>
<td>56.25%</td>
<td>★★★★☆☆</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們亞洲基本面強勁的未被發現的寶藏篩選器中的 2373 只股票的完整列表。</p>
<p>在這裏，我們突出了一些我們篩選器中首選的股票。</p>
<h2>山東威達機械（SZSE:002026）</h2>
<p><strong>Simply Wall St 價值評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> 山東威達機械有限公司專注於在中國及國際市場上製造和銷售鑽夾頭，市值為 71.9 億人民幣。</p>
<p><strong>運營：</strong> 威達機械的收入主要來自鑽夾頭的銷售，服務於國內和國際市場。公司的淨利潤率在最近的時期內顯示出波動，反映出運營效率和成本管理的變化。</p>
<p>山東威達機械作為機械行業的一個有前景的參與者，過去一年展現出 31.1% 的令人印象深刻的盈利增長，超過行業平均水平的 3.8%。公司的負債權益比在五年內從 0% 上升至 3.1%，但其利息支付仍然得到良好覆蓋，現金超過總債務。威達的交易價值估計低於其公允價格的 6.2%，儘管與去年相比銷售數字較低，但在 2025 年上半年報告的淨收入為 1.5787 億人民幣，反映出在公司結構和治理的戰略變化中持續盈利的韌性和潛力。</p>
<ul>
<li>點擊這裏發現山東威達機械的細節，查看我們的詳細分析健康報告。</li>
<li>通過我們的詳細歷史業績報告評估山東威達機械的過去表現。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/774ad231-4fd1-444a-9df5-971a1ed4854d/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/774ad231-4fd1-444a-9df5-971a1ed4854d/chart/debt-equity-history-analysis"/></p>
<p>截至 2025 年 10 月的 SZSE:002026 負債權益比</p>
<h2>浙江佐力藥業有限公司（SZSE:300181）</h2>
<p><strong>Simply Wall St 價值評級：</strong> ★★★★★★</p>
<p><strong>概述：</strong> 浙江佐力藥業有限公司從事中藥產品的研究、生產和營銷，市值為 132.1 億人民幣。</p>
<p><strong>運營：</strong> 浙江佐力藥業有限公司的收入主要來自中藥產品的銷售。公司的淨利潤率是評估其盈利能力時需要考慮的關鍵財務指標。</p>
<p>浙江佐力藥業作為製藥領域的一個活躍參與者，其令人印象深刻的財務指標引起了關注。公司在 2025 年上半年報告的淨收入為 3.735 億人民幣，較去年同期的 2.9605 億人民幣增長，展現出強勁的增長。其負債權益比在五年內顯著改善，從 28.1% 降至 20%。此外，去年盈利增長了 21.6%，預計未來每年將繼續保持類似的增長速度（21.2%）。以低於估計公允價值 41.2% 的顯著折扣交易，表明投資者在亞洲製藥行業尋找價值機會的潛在上行空間。</p>
<ul>
<li>在這裏深入瞭解浙江佐力藥業有限公司的具體情況，查看我們的詳細健康報告。</li>
<li>瞭解浙江佐力藥業有限公司的歷史表現。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/622eb9bb-56e4-4333-9ef3-063c670c87d3/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/622eb9bb-56e4-4333-9ef3-063c670c87d3/chart/debt-equity-history-analysis"/></p>
<p>截至 2025 年 10 月的 SZSE:300181 負債權益比</p>
<h2>安徽金春無紡布（SZSE:300877）</h2>
<p><strong>Simply Wall St 價值評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> 安徽金春無紡布有限公司專注於無紡布產品的生產和銷售，市值為 42.5 億人民幣。</p>
<p><strong>運營：</strong> 該公司主要通過生產和銷售無紡布產品來產生收入。其財務表現包括有效管理成本的重點，特別關注保持競爭力的淨利潤率。</p>
<p>安徽金春無紡布作為行業中的小型參與者，過去一年展現出 96.4% 的顯著盈利增長，超過奢侈品行業的同行。儘管最近股價波動，但其 2025 年上半年淨收入從去年的 173 萬人民幣激增至 1542 萬人民幣。公司在今年回購了價值 893 萬人民幣的 40 萬股股票，作為其早在四月宣佈的持續回購計劃的一部分。然而，需要注意的是，高質量的盈利受到去年截至 2025 年 6 月的 1300 萬人民幣的一次性收益的影響。</p>
<ul>
<li>在這份健康報告中解鎖我們對安徽金春無紡布股票分析的全面見解。</li>
<li>探索歷史數據，以跟蹤安徽金春無紡布的表現。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/ec667fba-0a3c-4139-82df-fc09ff5d826c/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/ec667fba-0a3c-4139-82df-fc09ff5d826c/chart/debt-equity-history-analysis"/></p>
<p>截至 2025 年 10 月的 SZSE:300877 債務與股本比率</p>
<h2>利用機會</h2>
<ul>
<li>深入瞭解我們在這裏識別的 2373 個具有強大基本面的亞洲未被發現的寶藏。</li>
<li>已經擁有這些公司？通過將您的投資組合與 Simply Wall St 連接，清晰化您的投資決策，輕鬆監控您股票的所有重要指標。</li>
<li>使用 Simply Wall St 掌控您的財務未來，向每位投資者提供國際市場的免費深入知識。</li>
</ul>
<h2>想探索一些替代方案嗎？</h2>
<ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>用顯示強勁增長潛力的公司充實您的投資組合，這些公司得到了分析師和管理層的樂觀展望支持。</li>
<li>尋找現金流潛力良好但交易價格低於其公允價值的公司。</li>
</ul>
<p><em>這篇文章由 Simply Wall St 撰寫，內容具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，僅使用無偏見的方法，我們的文章並不旨在提供財務建議。</strong> 這並不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>

山東威達

佐力藥業

<p>隨着全球市場面臨美國與中國之間重新加劇的貿易緊張局勢，投資者開始關注亞洲小型股的投資機會。山東威達機械、浙江佐力藥業和安徽金春無紡布因其強勁的基本面和增長潛力而受到關注。威達機械報告了 31.1% 的盈利增長，佐力藥業的淨收入上升至 3.735 億元人民幣，而安徽金春的盈利增長達 96.4%。這些公司在經濟不確定性中展現出韌性，使其成為當前市場中具有吸引力的投資選擇</p>

<p>As global markets navigate the complexities of renewed U.S.-China trade tensions and economic uncertainties, investors are increasingly looking towards small-cap stocks in Asia for potential opportunities. In this environment, identifying companies that demonstrate resilience and growth potential amid geopolitical challenges can be key to uncovering promising investments.</p>
<div class="lb-trans"><p>隨着全球市場應對美國與中國之間重新出現的貿易緊張局勢和經濟不確定性，投資者越來越關注亞洲的小型股以尋找潛在機會。在這種環境下，識別出在地緣政治挑戰中展現出韌性和增長潛力的公司，可能是發現有前景投資的關鍵。</p>
</div><h3>Top 10 Undiscovered Gems With Strong Fundamentals In Asia</h3>
<div class="lb-trans"><h3>亞洲基本面強勁的十大未被發現的寶藏</h3>
</div><table>
<thead>
<tr>
<th>Name</th>
<th>Debt To Equity</th>
<th>Revenue Growth</th>
<th>Earnings Growth</th>
<th>Health Rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Woori Technology Investment</td>
<td>NA</td>
<td>11.06%</td>
<td>-3.63%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Guangzhou Devotion Thermal Technology</td>
<td>6.90%</td>
<td>-5.77%</td>
<td>22.35%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Wuxi Chemical Equipment</td>
<td>NA</td>
<td>12.94%</td>
<td>1.09%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Tohoku Steel</td>
<td>NA</td>
<td>5.45%</td>
<td>0.39%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Hongmian Zhihui Science and Technology InnovationLtd.Guangzhou</td>
<td>12.09%</td>
<td>-20.53%</td>
<td>52.26%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Wholetech System Hitech</td>
<td>6.48%</td>
<td>14.41%</td>
<td>19.21%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Shenzhen Keanda Electronic Technology</td>
<td>3.22%</td>
<td>-6.05%</td>
<td>-14.83%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>CTCI Advanced Systems</td>
<td>33.93%</td>
<td>20.38%</td>
<td>21.25%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Jinlihua Electric</td>
<td>53.05%</td>
<td>9.84%</td>
<td>44.18%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Mirai Semiconductors</td>
<td>46.15%</td>
<td>10.52%</td>
<td>56.25%</td>
<td>★★★★☆☆</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>名稱</th>
<th>負債權益比</th>
<th>收入增長</th>
<th>盈利增長</th>
<th>健康評級</th>
</tr>
</thead>
<tbody>
<tr>
<td>Woori Technology Investment</td>
<td>NA</td>
<td>11.06%</td>
<td>-3.63%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>廣州德信熱能科技</td>
<td>6.90%</td>
<td>-5.77%</td>
<td>22.35%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>無錫化工設備</td>
<td>NA</td>
<td>12.94%</td>
<td>1.09%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>東北鋼鐵</td>
<td>NA</td>
<td>5.45%</td>
<td>0.39%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>紅綿智慧科技創新有限公司（廣州）</td>
<td>12.09%</td>
<td>-20.53%</td>
<td>52.26%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Wholetech System Hitech</td>
<td>6.48%</td>
<td>14.41%</td>
<td>19.21%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>深圳凱安電子科技</td>
<td>3.22%</td>
<td>-6.05%</td>
<td>-14.83%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>CTCI 先進系統</td>
<td>33.93%</td>
<td>20.38%</td>
<td>21.25%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>金利華電氣</td>
<td>53.05%</td>
<td>9.84%</td>
<td>44.18%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Mirai Semiconductors</td>
<td>46.15%</td>
<td>10.52%</td>
<td>56.25%</td>
<td>★★★★☆☆</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 2373 stocks from our Asian Undiscovered Gems With Strong Fundamentals screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們亞洲基本面強勁的未被發現的寶藏篩選器中的 2373 只股票的完整列表。</p>
</div><p>Here we highlight a subset of our preferred stocks from the screener.</p>
<div class="lb-trans"><p>在這裏，我們突出了一些我們篩選器中首選的股票。</p>
</div><h2>Shandong Weida Machinery (SZSE:002026)</h2>
<div class="lb-trans"><h2>山東威達機械（SZSE:002026）</h2>
</div><p><strong>Simply Wall St Value Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 價值評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Shandong Weida Machinery Co., Ltd. specializes in the manufacture and sale of drill chucks both in China and internationally, with a market cap of CN¥7.19 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 山東威達機械有限公司專注於在中國及國際市場上製造和銷售鑽夾頭，市值為 71.9 億人民幣。</p>
</div><p><strong>Operations:</strong> Weida Machinery generates revenue primarily from the sale of drill chucks, catering to both domestic and international markets. The company's net profit margin has shown variability over recent periods, reflecting changes in operational efficiency and cost management.</p>
<div class="lb-trans"><p><strong>運營：</strong> 威達機械的收入主要來自鑽夾頭的銷售，服務於國內和國際市場。公司的淨利潤率在最近的時期內顯示出波動，反映出運營效率和成本管理的變化。</p>
</div><p>Shandong Weida Machinery, a promising player in the machinery sector, has demonstrated impressive earnings growth of 31.1% over the past year, outpacing the industry average of 3.8%. The company's debt to equity ratio rose from 0% to 3.1% over five years, yet it remains well-covered for interest payments with more cash than total debt. Trading at a value estimated to be 6.2% below its fair price, Weida reported net income of CNY 157.87 million for the first half of 2025 despite lower sales figures compared to last year, reflecting resilience and potential for continued profitability amidst strategic changes in company structure and governance.</p>
<div class="lb-trans"><p>山東威達機械作為機械行業的一個有前景的參與者，過去一年展現出 31.1% 的令人印象深刻的盈利增長，超過行業平均水平的 3.8%。公司的負債權益比在五年內從 0% 上升至 3.1%，但其利息支付仍然得到良好覆蓋，現金超過總債務。威達的交易價值估計低於其公允價格的 6.2%，儘管與去年相比銷售數字較低，但在 2025 年上半年報告的淨收入為 1.5787 億人民幣，反映出在公司結構和治理的戰略變化中持續盈利的韌性和潛力。</p>
</div><ul>
<li>Click here to discover the nuances of Shandong Weida Machinery with our detailed analytical health report.</li>
<li>Assess Shandong Weida Machinery's past performance with our detailed historical performance reports.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏發現山東威達機械的細節，查看我們的詳細分析健康報告。</li>
<li>通過我們的詳細歷史業績報告評估山東威達機械的過去表現。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/774ad231-4fd1-444a-9df5-971a1ed4854d/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/774ad231-4fd1-444a-9df5-971a1ed4854d/chart/debt-equity-history-analysis"/></p>
<p>SZSE:002026 Debt to Equity as at Oct 2025</p>
<div class="lb-trans"><p>截至 2025 年 10 月的 SZSE:002026 負債權益比</p>
</div><h2>Zhejiang Jolly PharmaceuticalLTD (SZSE:300181)</h2>
<div class="lb-trans"><h2>浙江佐力藥業有限公司（SZSE:300181）</h2>
</div><p><strong>Simply Wall St Value Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 價值評級：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Zhejiang Jolly Pharmaceutical Co., LTD is involved in the research, production, and marketing of Chinese medicinal products both domestically and internationally, with a market cap of CN¥13.21 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 浙江佐力藥業有限公司從事中藥產品的研究、生產和營銷，市值為 132.1 億人民幣。</p>
</div><p><strong>Operations:</strong> Zhejiang Jolly Pharmaceutical Co., LTD generates revenue primarily through the sale of Chinese medicinal products. The company's net profit margin is a key financial metric to consider when evaluating its profitability.</p>
<div class="lb-trans"><p><strong>運營：</strong> 浙江佐力藥業有限公司的收入主要來自中藥產品的銷售。公司的淨利潤率是評估其盈利能力時需要考慮的關鍵財務指標。</p>
</div><p>Zhejiang Jolly Pharma, a dynamic player in the pharmaceutical space, has been making waves with its impressive financial metrics. The company reported net income of CNY 373.5 million for the first half of 2025, up from CNY 296.05 million a year earlier, showcasing robust growth. Its debt-to-equity ratio improved significantly over five years from 28.1% to 20%. Moreover, earnings grew by an impressive 21.6% last year and are forecasted to continue at a similar pace annually (21.2%). Trading at a substantial discount of 41.2% below estimated fair value suggests potential upside for investors seeking value opportunities in Asia's pharmaceutical sector.</p>
<div class="lb-trans"><p>浙江佐力藥業作為製藥領域的一個活躍參與者，其令人印象深刻的財務指標引起了關注。公司在 2025 年上半年報告的淨收入為 3.735 億人民幣，較去年同期的 2.9605 億人民幣增長，展現出強勁的增長。其負債權益比在五年內顯著改善，從 28.1% 降至 20%。此外，去年盈利增長了 21.6%，預計未來每年將繼續保持類似的增長速度（21.2%）。以低於估計公允價值 41.2% 的顯著折扣交易，表明投資者在亞洲製藥行業尋找價值機會的潛在上行空間。</p>
</div><ul>
<li>Dive into the specifics of Zhejiang Jolly PharmaceuticalLTD here with our thorough health report.</li>
<li>Learn about Zhejiang Jolly PharmaceuticalLTD's historical performance.</li>
</ul>
<div class="lb-trans"><ul>
<li>在這裏深入瞭解浙江佐力藥業有限公司的具體情況，查看我們的詳細健康報告。</li>
<li>瞭解浙江佐力藥業有限公司的歷史表現。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/622eb9bb-56e4-4333-9ef3-063c670c87d3/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/622eb9bb-56e4-4333-9ef3-063c670c87d3/chart/debt-equity-history-analysis"/></p>
<p>SZSE:300181 Debt to Equity as at Oct 2025</p>
<div class="lb-trans"><p>截至 2025 年 10 月的 SZSE:300181 負債權益比</p>
</div><h2>AnHui Jinchun Nonwoven (SZSE:300877)</h2>
<div class="lb-trans"><h2>安徽金春無紡布（SZSE:300877）</h2>
</div><p><strong>Simply Wall St Value Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 價值評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> AnHui Jinchun Nonwoven Co., Ltd. specializes in the production and sale of nonwoven products, with a market capitalization of CN¥4.25 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 安徽金春無紡布有限公司專注於無紡布產品的生產和銷售，市值為 42.5 億人民幣。</p>
</div><p><strong>Operations:</strong> The company generates revenue primarily from the production and sale of nonwoven products. Its financial performance includes a focus on managing costs effectively, with particular attention to maintaining a competitive net profit margin.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司主要通過生產和銷售無紡布產品來產生收入。其財務表現包括有效管理成本的重點，特別關注保持競爭力的淨利潤率。</p>
</div><p>AnHui Jinchun Nonwoven, a small player in the industry, has shown remarkable earnings growth of 96.4% over the past year, outpacing its peers in the luxury sector. Despite a volatile share price recently, their net income surged to CN¥15.42 million for the first half of 2025 from CN¥1.73 million last year. The company repurchased 400,000 shares worth CN¥8.93 million this year as part of its ongoing buyback program announced earlier in April. However, it's important to note that high-quality earnings are impacted by significant one-off gains amounting to CN¥13 million over the last year ending June 2025.</p>
<div class="lb-trans"><p>安徽金春無紡布作為行業中的小型參與者，過去一年展現出 96.4% 的顯著盈利增長，超過奢侈品行業的同行。儘管最近股價波動，但其 2025 年上半年淨收入從去年的 173 萬人民幣激增至 1542 萬人民幣。公司在今年回購了價值 893 萬人民幣的 40 萬股股票，作為其早在四月宣佈的持續回購計劃的一部分。然而，需要注意的是，高質量的盈利受到去年截至 2025 年 6 月的 1300 萬人民幣的一次性收益的影響。</p>
</div><ul>
<li>Unlock comprehensive insights into our analysis of AnHui Jinchun Nonwoven stock in this health report.</li>
<li>Explore historical data to track AnHui Jinchun Nonwoven's performance over time in our Past section.</li>
</ul>
<div class="lb-trans"><ul>
<li>在這份健康報告中解鎖我們對安徽金春無紡布股票分析的全面見解。</li>
<li>探索歷史數據，以跟蹤安徽金春無紡布的表現。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/ec667fba-0a3c-4139-82df-fc09ff5d826c/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/ec667fba-0a3c-4139-82df-fc09ff5d826c/chart/debt-equity-history-analysis"/></p>
<p>SZSE:300877 Debt to Equity as at Oct 2025</p>
<div class="lb-trans"><p>截至 2025 年 10 月的 SZSE:300877 債務與股本比率</p>
</div><h2>Taking Advantage</h2>
<div class="lb-trans"><h2>利用機會</h2>
</div><ul>
<li>Dive into all 2373 of the Asian Undiscovered Gems With Strong Fundamentals we have identified here.</li>
<li>Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.</li>
<li>Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor.</li>
</ul>
<div class="lb-trans"><ul>
<li>深入瞭解我們在這裏識別的 2373 個具有強大基本面的亞洲未被發現的寶藏。</li>
<li>已經擁有這些公司？通過將您的投資組合與 Simply Wall St 連接，清晰化您的投資決策，輕鬆監控您股票的所有重要指標。</li>
<li>使用 Simply Wall St 掌控您的財務未來，向每位投資者提供國際市場的免費深入知識。</li>
</ul>
</div><h2>Want To Explore Some Alternatives?</h2>
<div class="lb-trans"><h2>想探索一些替代方案嗎？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
<li>Find companies with promising cash flow potential yet trading below their fair value.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>用顯示強勁增長潛力的公司充實您的投資組合，這些公司得到了分析師和管理層的樂觀展望支持。</li>
<li>尋找現金流潛力良好但交易價格低於其公允價值的公司。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>這篇文章由 Simply Wall St 撰寫，內容具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，僅使用無偏見的方法，我們的文章並不旨在提供財務建議。</strong> 這並不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
</div>

山東威達機械及其他兩傢俱有潛力的亞洲小盤股